HeartSciences (NASDAQ:HSCS) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of HeartSciences (NASDAQ:HSCS) to a sell rating in a research report report published on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HeartSciences in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $8.00.

HeartSciences Stock Performance

HeartSciences stock opened at $3.39 on Friday. HeartSciences has a fifty-two week low of $1.63 and a fifty-two week high of $4.35. The company has a market capitalization of $13.22 million, a price-to-earnings ratio of -0.86 and a beta of 1.85. The stock has a fifty day moving average of $2.67 and a two-hundred day moving average of $2.39.

HeartSciences (NASDAQ:HSCS) last posted its quarterly earnings data on Thursday, July 23rd. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.22). On average, analysts forecast that HeartSciences will post -3.04 EPS for the current fiscal year.

Hedge Funds Weigh In On HeartSciences

An institutional investor recently raised its position in HeartSciences stock. DRW Securities LLC boosted its holdings in HeartSciences Inc. (NASDAQ:HSCS) by 13.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 95,065 shares of the company’s stock after buying an additional 11,455 shares during the period. DRW Securities LLC owned 2.99% of HeartSciences worth $294,000 at the end of the most recent reporting period. Institutional investors own 17.24% of the company’s stock.

About HeartSciences

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.